Literature DB >> 9827924

Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Français d'Hématologie Cellulaire.

R Garand1, J Goasguen, A Brizard, J Buisine, A Charpentier, J F Claisse, E Duchayne, M Lagrange, C Segonds, X Troussard, G Flandrin.   

Abstract

T-prolymphocytic leukaemia (T-PLL) is a rare disorder with a poor outcome. Presentation features were studied in 78 T-PLL cases. Although 53 patients (group A) presented with typical progressive disease including rapidly increasing leucocytosis. 25 patients (group B) experienced an initial indolent clinical course with stable moderate leucocytosis. The morphology and antigenic profile of abnormal cells were similar in both groups, except for a lower incidence of CD45RO+ CD45RA- pattern in group B. A high incidence of inv(14)(q11;q32), t(14;14)(q11;q32) and i(8)(q10) chromosomal abnormalities were found in both groups. After an initial indolent phase (median 33 months; 6-103 months), 16 group B patients progressed to an aggressive stage with clinical and laboratory features similar to group A. Moreover, median survival after progression was short in both groups. In conclusion, T-PLL may start as an indolent disease similar to that reported in ataxia telangectasia. In this rare genetic disorder, some patients develop stable T-cell clones which progress toward T-PLL-like leukaemia. Moreover, ATM gene mutations have been reported in T-PLL. Thus, both diseases are likely to be closely related.

Entities:  

Mesh:

Year:  1998        PMID: 9827924     DOI: 10.1046/j.1365-2141.1998.00977.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  21 in total

1.  Concurrent Hodgkin's disease (mixed cellularity type) and T-cell chronic lymphocytic leukemia/prolymphocytic leukemia.

Authors:  A Miyata; K Kojima; T Yoshino; S Fujii; K Shinagawa; K Ichimura
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

2.  T-cell prolymphocytic leukemia in Japan: is it a variant?

Authors:  Junichi Kameoka; Naoto Takahashi; Hideyoshi Noji; Kazunori Murai; Katsushi Tajima; Yoshihiro Kameoka; Shinji Sato; Tsutomu Shichishima; Yoji Ishida; Hideo Harigae; Kenichi Sawada
Journal:  Int J Hematol       Date:  2012-04-24       Impact factor: 2.490

Review 3.  T-cell prolymphocytic leukemia.

Authors:  Claire E Dearden
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 4.  Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.

Authors:  Philipp B Staber; Marco Herling; Mar Bellido; Eric D Jacobsen; Matthew S Davids; Tapan Mahendra Kadia; Andrei Shustov; Olivier Tournilhac; Emmanuel Bachy; Francesco Zaja; Kimmo Porkka; Gregor Hoermann; Ingrid Simonitsch-Klupp; Claudia Haferlach; Stefan Kubicek; Marius E Mayerhoefer; Georg Hopfinger; Ulrich Jaeger; Claire Dearden
Journal:  Blood       Date:  2019-07-10       Impact factor: 22.113

5.  Cerebriform variant type of T cell prolymphocytic leukemia with complex karyotype including an additional segment at 1p36.1.

Authors:  Senji Kasahara; Hisashi Tsurumi; Yuhei Shibata; Takuro Matsumoto; Nobuhiko Nakamura; Hiroshi Nakamura; Nobuhiro Kanemura; Naoe Goto; Takeshi Hara; Hisataka Moriwaki
Journal:  Int J Hematol       Date:  2012-10-05       Impact factor: 2.490

6.  TCL1A gene involvement in T-cell prolymphocytic leukemia in Japanese patients.

Authors:  Akihiko Yokohama; Akio Saitoh; Hirotaka Nakahashi; Takeki Mitsui; Hiromi Koiso; Yoshitora Kim; Hideki Uchiumi; Takayuki Saitoh; Hiroshi Handa; Takahiro Jimbo; Kayoko Murayama; Tohru Sakura; Hirokazu Murakami; Masamitsu Karasawa; Yoshihisa Nojima; Norifumi Tsukamoto
Journal:  Int J Hematol       Date:  2011-12-23       Impact factor: 2.490

Review 7.  Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.

Authors:  Aude Collignon; Anne Wanquet; Elsa Maitre; Edouard Cornet; Xavier Troussard; Thérèse Aurran-Schleinitz
Journal:  Curr Oncol Rep       Date:  2017-04       Impact factor: 5.075

Review 8.  Peripheral T-cell lymphoma.

Authors:  Wing Y Au; Raymond Liang
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

9.  High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Michael A Teitell; Marina Konopleva; Farhad Ravandi; Ryuji Kobayashi; Dan Jones
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

Review 10.  Alemtuzumab in T-cell malignancies.

Authors:  Claire E Dearden; Estella Matutes; Daniel Catovsky
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.